NDLI: Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer

Content Provider	PubMed Central
Author	Banno, Kouji Iida, Miho Yanokura, Megumi Irie, Haruko Masuda, Kenta Kobayashi, Yusuke Tominaga, Eiichiro Aoki, Daisuke
Copyright Year	2015
Abstract	The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX-2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K-Akt-mTOR pathway by activating LKB1-AMPK and reduction of insulin and insulin-like growth factor-1 due to AMPK activation. COX-2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX-2. PGE2 maintains high expression of COX-2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX-2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug reactions. Thus, drug repositioning may become a key approach for gynecologic cancer in drug discovery.
Related Links	http://dx.doi.org/10.1155/2015/341362
Starting Page	341362
File Format	PDF
ISSN	1537744X
e-ISSN	1537744X
Journal	The Scientific World Journal
Volume Number	2015
Language	English
Publisher	Hindawi Publishing Corporation
Publisher Date	2015-01-01
Access Restriction	Open
Rights Holder	Hindawi Publishing Corporation
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Medicine Biochemistry, Genetics and Molecular Biology Environmental Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer

Drug repositioning in sarcomas and other rare tumors

Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer

Repositioning of new potential schistosomicidal drugs using chemogenomic strategy

Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy

Targeting Mitochondria as Therapeutic Strategy for Metabolic Disorders

A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer

Gaining Surgical Access for Repositioning the Inferior Alveolar Neurovascular Bundle

Mechanism of and Therapeutic Strategy for Atrial Fibrillation Associated with Diabetes Mellitus

Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer

Similar Documents

Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer

Drug repositioning in sarcomas and other rare tumors

Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer

Repositioning of new potential schistosomicidal drugs using chemogenomic strategy

Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy

Targeting Mitochondria as Therapeutic Strategy for Metabolic Disorders

A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer

Gaining Surgical Access for Repositioning the Inferior Alveolar Neurovascular Bundle

Mechanism of and Therapeutic Strategy for Atrial Fibrillation Associated with Diabetes Mellitus

Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer